Baker Ellis Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.28M Sell
14,950
-300
-2% -$46K 0.27% 77
2025
Q4
$2.1M Buy
15,250
+539
+4% +$70.6K 0.25% 78
2025
Q3
$1.89M Buy
14,711
+150
+1% +$18.3K 0.23% 80
2025
Q2
$1.76M Buy
14,561
+2,200
+18% +$248K 0.24% 76
2025
Q1
$1.38M Buy
12,361
+1,034
+9% +$110K 0.2% 92
2024
Q4
$1.1M Sell
11,327
-557
-5% -$59.4K 0.16% 94
2024
Q3
$1.37M Sell
11,884
-125
-1% -$14.2K 0.19% 91
2024
Q2
$1.28M Sell
12,009
-160
-1% -$16.1K 0.19% 90
2024
Q1
$1.18M Sell
12,169
-600
-5% -$61.5K 0.18% 103
2023
Q4
$1.29M Hold
12,769
0.21% 92
2023
Q3
$1.3M Sell
12,769
-250
-2% -$25.4K 0.23% 85
2023
Q2
$1.31M Sell
13,019
-100
-0.8% -$10K 0.22% 86
2023
Q1
$1.21M Sell
13,119
-500
-4% -$43.7K 0.22% 89
2022
Q4
$1.24M Sell
13,619
-123
-0.9% -$10.4K 0.24% 83
2022
Q3
$1.04M Sell
13,742
-153
-1% -$12.7K 0.23% 84
2022
Q2
$1.18M Buy
13,895
+26
+0.2% +$2.28K 0.24% 83
2022
Q1
$1.22M Buy
13,869
+100
+0.7% +$8.66K 0.22% 89
2021
Q4
$1.2M Sell
13,769
-260
-2% -$21.6K 0.21% 91
2021
Q3
$1.15M Sell
14,029
-479
-3% -$43.1K 0.22% 92
2021
Q2
$1.32M Sell
14,508
-3,301
-19% -$294K 0.26% 83
2021
Q1
$1.52M Sell
17,809
-920
-5% -$82.6K 0.33% 75
2020
Q4
$1.77M Sell
18,729
-180
-1% -$15.7K 0.42% 64
2020
Q3
$1.64M Sell
18,909
-382
-2% -$33.1K 0.46% 60
2020
Q2
$1.69M Sell
19,291
-450
-2% -$38.8K 0.5% 57
2020
Q1
$1.63M Sell
19,741
-2,000
-9% -$178K 0.58% 45
2019
Q4
$2.06M Sell
21,741
-600
-3% -$53.8K 0.57% 51
2019
Q3
$1.94M Sell
22,341
-2,340
-9% -$210K 0.52% 57
2019
Q2
$2.25M Sell
24,681
-3,951
-14% -$334K 0.6% 45
2019
Q1
$2.47M Sell
28,632
-921
-3% -$73.9K 0.69% 41
2018
Q4
$2.27M Sell
29,553
-937
-3% -$72.9K 0.69% 40
2018
Q3
$2.35M Sell
30,490
-11,657
-28% -$862K 0.61% 47
2018
Q2
$2.85M Sell
42,147
-6,292
-13% -$434K 0.75% 37
2018
Q1
$3.51M Sell
48,439
-770
-2% -$58.6K 0.92% 26
2017
Q4
$3.7M Buy
49,209
+558
+1% +$42.1K 0.93% 28
2017
Q3
$3.74M Sell
48,651
-614
-1% -$46.4K 0.99% 25
2017
Q2
$3.69M Buy
49,265
+1,507
+3% +$107K 1.01% 27
2017
Q1
$3.18M Sell
47,758
-112
-0.2% -$7.46K 0.91% 27
2016
Q4
$3.12M Buy
47,870
+357
+0.8% +$23.2K 0.92% 28
2016
Q3
$3.36M Buy
47,513
+139
+0.3% +$10.1K 1.01% 23
2016
Q2
$3.5M Buy
47,374
+837
+2% +$57.8K 1.1% 21
2016
Q1
$3.02M Buy
46,537
+21
+0% +$1.43K 1% 21
2015
Q4
$3.59M Buy
46,516
+167
+0.4% +$13.3K 1.23% 19
2015
Q3
$3.82M Buy
46,349
+94
+0.2% +$8.37K 1.36% 15
2015
Q2
$4.08M Sell
46,255
-2,959
-6% -$271K 1.37% 14
2015
Q1
$4.35M Sell
49,214
-399
-0.8% -$35.4K 1.38% 14
2014
Q4
$4.12M Sell
49,613
-446
-0.9% -$37K 1.38% 15
2014
Q3
$4.22M Hold
50,059
1.46% 11
2014
Q2
$4.06M Sell
50,059
-1,655
-3% -$130K 1.38% 12
2014
Q1
$3.94M Sell
51,714
-2,698
-5% -$197K 1.36% 11
2013
Q4
$3.92M Sell
54,412
-708
-1% -$49.2K 1.36% 14
2013
Q3
$3.79M Sell
55,120
-360
-0.6% -$23.8K 1.43% 13
2013
Q2
$3.52M Buy
+55,480
New +$3.61M 1.4% 12

Other funds holding NVS

Baker Ellis Asset Management's NVS Position: Q1 2026 in Review

Baker Ellis Asset Management reduced its Novartis (NVS) stake by 2% in Q1 2026, selling an estimated $46K and leaving 14,950 shares worth $2.28M. The position accounts for 0.27% of the portfolio, ranked #77.

Baker Ellis Asset Management first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.35M in Q1 2015. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Baker Ellis Asset Management held 14,950 shares of Novartis worth $2.28M as of Q1 2026.
  • Baker Ellis Asset Management sold 300 Novartis shares in Q1 2026, an estimated $46K.
  • Novartis made up 0.27% of Baker Ellis Asset Management's portfolio in Q1 2026, its #77 holding.
  • Baker Ellis Asset Management first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Baker Ellis Asset Management's Novartis position peaked at $4.35M in Q1 2015.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Baker Ellis Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.